NEW YORK (
) has been upgraded by TheStreet Ratings from sell to hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and weak operating cash flow.
Derma Sciences, Inc. engages in manufacturing, marketing, and selling wound care, wound closure and specialty securement devices, and skin care products. Derma has a market cap of $70.5 million and is part of the
industry. Shares are up 131.9% year to date as of the close of trading on Monday.